Initiation of Phase 1b study using SGT-212 for the treatment of patients with Friedreich's Ataxia expected in 2H25. Click ...

Orphan drugs offer critical treatment options for rare diseases, improving quality of life for underserved patients and ...

The UK government has launched a £150 million ($185 million) procurement drive for artificial intelligence solutions that can ...

Analyst Michael Ulz of Morgan Stanley maintained a Buy rating on Dyne Therapeutics (DYN – Research Report), retaining the price target of ...

The methods and protocols generated in this study are accessible and can be implemented in any standard research laboratory without the need for ...

Stifel analysts began coverage of Edgewise Therapeutics (NASDAQ:EWTX), currently valued at $2.6 billion, with a Hold rating and set a price target of $30.00. According to InvestingPro data, the stock ...

Oppenheimer reiterated its Outperform rating on Dyne Therapeutics (NASDAQ:DYN), maintaining a $60.00 price target, ...

FSHD is the second most common form of muscular dystrophy after the Duchenne type, and affects around 1 million people worldwide, with no approved treatments. It tends to cause muscle wasting in ...

The FDA has granted fast-track designation to an investigational antisense oligonucleotide to treat individuals with myotonic ...

Edgewise Therapeutics, Inc., , a leading muscle disease biopharmaceutical company, today announced key changes to its executive team that will strengthen its leadership and sharpen the Company's focus ...

This year, my colleagues have selected me to lead the Senate Armed Services Committee (SASC). I am eager to take on the responsibilities of the role, because the committee’s work ...

The Perrysburg gymnastics team hosted the area’s only All Around Invitational on January 20 — the Noah Ninja’s meet: ...